Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats
Open Access
- 7 February 2020
- journal article
- research article
- Published by Elsevier BV in Molecular Therapy Nucleic Acids
- Vol. 20, 73-85
- https://doi.org/10.1016/j.omtn.2020.01.036
Abstract
No abstract availableFunding Information
- Italian Association for Cancer Research (9980, 9980)
This publication has 51 references indexed in Scilit:
- In Vitro and In Vivo Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma CellsClinical Cancer Research, 2013
- miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1Cell Death & Disease, 2012
- Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic modelJournal of Hepatology, 2012
- Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytesNucleic Acids Research, 2011
- MiR-221 and miR-222 target PUMA to induce cell survival in glioblastomaMolecular Cancer, 2010
- MicroRNA-221/222 Confers Tamoxifen Resistance in Breast Cancer by Targeting p27Kip1Online Journal of Public Health Informatics, 2008
- Most mammalian mRNAs are conserved targets of microRNAsGenome Research, 2008
- MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinomaOncogene, 2008
- MicroRNA signatures of TRAIL resistance in human non-small cell lung cancerOncogene, 2008
- No PUMA, no death: Implications for p53-dependent apoptosisCancer Cell, 2003